Kits, compositions and methods for detecting a biological condition

1. A method for assaying for possible infection or sepsis in a subject, comprising:

a) applying a blood sample from the subject into a single-use microfluidic test cartridge, the test cartridge comprising:

i) a sample composition chamber adapted for receiving the blood sample;

ii) a first pre-filled microfluidic blister comprising an antibody mixture comprising fluorescently tagged CD64 and fluorescently tagged CD 163 antibodies;

iii) a second pre-filled microfluidic blister comprising a cell lysis reagent;

iv) a third pre-filled microfluidic blister comprising fluorescently tagged beads having a fluorescent tag different than the fluorescent tag of the CD64 and the fluorescent tag of the CD163 antibodies;

v) a treatment compartment adapted for fluid mixing, wherein the treatment compartment is in fluid communication with the sample composition chamber, the first pre-filled microfluidic blister, the second pre-filled microfluidic blister, and the third pre-filled microfluidic blister;

vi) a bellow element fluidly connected to the treatment compartment;

vii) an evaluation chamber fluidly connected to the treatment compartment and comprising a reading zone;

b) inserting the test cartridge into a cartridge handling unit (CHU) wherein the CHU is pre-programmed to perform the following steps:

i) pressing the first pre-filled microfluidic blister thereby releasing the antibody mixture into the treatment compartment;

ii) mixing at least a portion of the blood sample and the antibody mixture in the treatment compartment for a predetermined period of time using the bellow element;

iii) pressing the second pre-filled microfluidic blister thereby releasing the cell lysis reagent into the treatment compartment;

iv) mixing the blood sample, the antibody mixture, and the cell lysis reagent in the treatment compartment for a predetermined period of time using the bellow element;

v) pressing the third pre-filled microfluidic blister thereby releasing the fluorescently tagged beads into the treatment compartment;

vi) mixing in the treatment compartment for a predetermined period of time, at least a portion of the blood sample, the antibody mixture, the cell lysis reagent, and the fluorescently tagged beads, thereby forming a final mixture;

vii) flowing individual blood cells and beads through the reading zone in the evaluation chamber;

viii) measuring fluorescent signals of fluorescently tagged blood cells using an optoelectronic unit;

ix) measuring fluorescent signals of the fluorescently tagged beads using the optoelectronic unit;

x) determining median fluorescence signal from the fluorescently tagged blood cells;

xi) determining median fluorescence signal from the fluorescently tagged beads;

xii) determining a ratio of the median fluorescence signals from steps (x) and (xi);

xiii) using the ratio to provide an index score representative of the possibility of infection or sepsis in the subject.

2. A method for assaying for possible infection or sepsis in a subject, comprising:

in a single-use microfluidic cartridge comprising a single-use blister, combining (i) a blood sample from the subject, (ii) an antibody mixture comprising fluorescently tagged CD64 and fluorescently tagged CD163 antibodies, (iii) fluorescently tagged beads having a fluorescent tag different than the antibody mixture, and (iv) a lysis reagent to thereby generate a final mixture;

in the single-use microfluidic cartridge, mixing the final mixture using a bellow element;

in the single-use microfluidic cartridge, flowing cells and beads from the final mixture into an evaluation chamber comprising a reading zone;

measuring fluorescent signals of fluorescently tagged blood cells using an optoelectronic unit;

measuring fluorescent signals of the fluorescently tagged beads using the optoelectronic unit;

determining median fluorescence signal from the fluorescently tagged blood cells;

determining median fluorescence signal from the fluorescently tagged beads;

determining a ratio of the median fluorescence signals from the fluorescently tagged blood cells and the fluorescently tagged beads; and

using the ratio to provide an index score representative of the possibility of infection or sepsis in the subject.

3. The method of claim 1 or 2 , wherein the test cartridge further comprises a pump or an air blowing element.

4. The method of claim 1 or 2 , wherein the test cartridge is valveless.

5. The method of claim 1 or 2 , wherein the volume of any of the microfluidic blisters is from about 1 microliter to 1000 microliters.

6. The method of claim 1 or 2 , wherein the volume of the blood in the final mixture is about 10 microliters.

7. The method of claim 1 , wherein the test cartridge based steps from the step of inserting the test cartridge into the CHU to the step of providing an index score are performed in less than 15 minutes.

8. The method of claim 2 , wherein the steps from the step of combining the blood sample from the subject to the step of providing an index score are performed in less than 15 minutes.

9. The method of claim 1 or 2 , wherein the cartridge further comprises a tortuous shaped channel.

10. The method of claim 1 or 2 , wherein the fluorescently labeled beads comprise Starfire Red.

11. The method of claim 1 , wherein the blood is whole blood.

12. The method of claim 1 , wherein the cells comprise erythrocytes or leukocytes, and wherein the leukocytes comprise lymphocytes or neutrophils.

13. The method of claim 3 , wherein the lysis reagent comprises ammonium chloride.

14. The method of claim 3 , wherein, the antibodies are murine monoclonal antibodies.

15. The method of claim 1 or 2 , wherein determining comprises employing at least one of crosscorrelation algorithm, boxar averaging algorithm, filtering algorithm or minimum mean square error fit.

16. The method of claim 1 or 2 , further comprising determining the type of the cells.